BiopSense

Automated sample processing for liquid biopsies: a cartridge-based instrument that extracts cell-free DNA from blood more sensitively and with less manual work, for monitoring cancer treatment and organ transplants. Grew out of Prof. Marja Tiirola's research at the University of Jyväskylä; market launch targeted for 2026.

The row

Sector

Medtech & Digital Health

Stage

Pre-revenue — No sales yet

Location

Jyväskylä

Founded

2019

Research origin

Univ. of Jyväskylä

Business ID

2958574-3 · Finnish trade register

Funding

€2.5M EIC Transition grant (JYU, 1/2022); University of Jyväskylä's Unifund among investors

Links

Where this sits on the map

BiopSense is one of 34 companies in Medtech & Digital Health. The others:

How this row was decided

Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗